

MGH-HKU-Nature China Forum

MOLECULAR MEDICINE AND BIOPHARMA OPPORTUNITIES

China is increasingly becoming an attractive destination for biotechnology and pharmaceutical research, and the MGH-HKU-Nature China Forum will highlight the opportunities and challenges in this rapidly evolving country. This two-day forum will bring together leading academic and industry scientists worldwide to discuss the advances in molecular medicine in China, and identify important market opportunities – from stem cell research to cardiovascular disease. Senior industry executives will reveal how China is playing a key role in biotechnology and pharmaceutical R&D, provide first-hand experiences of navigating the unique and complex scientific, regulatory and intellectual property issues, and discuss the current and future environment for partnering strategies. The MGH-HKU-Nature China Forum will be of interest to any scientific or business leader who is looking to explore China's growing potential.

March 5-6, 2007
The University of Hong Kong
Early bird registration & abstract submission deadline
January 31, 2007

AGENDA

"Translational Medicine Landscape in China"

Session 1: Research Opportunities in China

- Infectious Diseases Research
- Stem Cell Research
- Chemical Biology

Session 2: Chronic Diseases in China

- Cardiovascular and Metabolic Diseases Research

"Biotechnology and Pharmaceutical Landscape in China"

Session 3: Fostering Innovation in China

- Biotechnology and Pharmaceutical Opportunities in China
- Intellectual Property in China

Session 4: Mining China's Resources

- Financing and Fundraising in China
- Clinical Trials

Speakers list

- James Cai (AstraZeneca Pharmaceutical Company)
- Li Chen (Roche R&D Centre China)
- Ling Chen (Guangzhou Institute of Biomedicine and Health)
- Zhu Chen (Chinese Academy of Sciences)
- Kenneth R Chien (Harvard Medical School, Harvard Stem Cell Institute)
- Yi Guan (Department of Microbiology, The University of Hong Kong)
- David Ho (Aaron Diamond AIDS Research Center)
- Hualiang Jiang (Shanghai Institute of Materia Medica)
- Johan Karlberg (Clinical Trials Centre, The University of Hong Kong)
- William Keller (Keller Pharma Consultancy, Shanghai)
- George King (Vascular Research, Joslin Clinic and Harvard Medical School)
- En Li (Novartis Institutes for Biomedical Research)
- Evan Loh (Clinical R & D, Wyeth Pharmaceuticals)
- Douglas Melton (Department of Molecular and Cellular Biology, Harvard University)
- Elizabeth Nabel (National Heart, Lung, and Blood Institute, National Institutes of Health)
- Zihe Rao (Laboratory of Structural Biology, Tsinghua University)
- Huizhen Sheng (Center for Developmental Biology, Xinhua Hospital)
- Paul Vanhoutte (Department of Pharmacology, The University of Hong Kong)
- David Wong (School of Medicine, Indiana University)
- Jerry Yang (Department of Animal Science, University of Connecticut)

a nature conference


For more information go to: www.nature.com/nature/meetings/china



MASSACHUSETTS
GENERAL HOSPITAL



120
Years of Medical Education

nature publishing group 

General contact information:

International Conference Consultants, Ltd. T: (852) 2559 9973 F: (852) 2547 9528 E: nature2007@icc.com.hk